Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Today's PRE 14C just killed this POS. So much for any hope that they are trying to get back to .01/share
Dilution is just starting...LOL. OTC website shows 181,550,547 shares outstanding as of 2/1/2019, but wait, now it's 512,259,019...LOL
PRE 14C released 2/20/2019:
"As of February 19, 2019, there were 512,259,019 shares of Common Stock issued and outstanding"
Like what??????
100% agree Catfish...what a cluster f**k
Looks ready....for another round of pumping and dumping.
Guess that implies that Wdnesdays count. Be back tomorrow to check...LOL
Malincrock of sh*t! Malincrock of sh*t!
LOL!!!!!!!!!! Today was tomorrow yesterday.
How ironic...ONSCAMILIX is about to be delisted from OTCQB status then they pull an insignificant filing out of their hat to keep their status. 10 million shares...LOL. Why would Biovectra even bother with a POS like this. Former director of Biovectra now current director of ONSCAMILIX saved the day, at least temporarily.
Going back to .001 this is just the process of dilution and the work of scam artists
Ok, it was released January, dated Nov 28,2018...picky, picky, picky
I DOUBT IT....LOL
8-K Dated November 29, 2018
Item 8.01 Other Events
The Company is halting enrollment in its Phase I clinical trial of Prolanta for the treatment of ovarian cancer as a result of injection site reactions at the current dose level. No other adverse effects or signs of toxicity have been observed for the drug.
Two subjects enrolled in the second dosing group, 1 mg per kg of body weight, have experienced inflammation and edema at the injection sites that resulted in their withdrawal from the study. Prolanta is injected subcutaneously daily during the treatment period. The Company believes that a reformulation or alternative dosing method of the drug will be required to continue the clinical evaluation of the drug, and such changes may require additional preclinical toxicity studies and additional clearance by the U.S. Food and Drug Administration. The Company does not have the financial resources at this time to conduct such additional studies.
Whale Team about to get harpooned...LOL
.000001 after they approve of the bankruptcy....LOL
10mil shares from BioVectra is a drop in the bucket. Director Zajicek trying hard to bail out his company using ties to his old company.
S-1/A
"Dale Zajicek. Mr. Zajicek has served as a director of the Company since September 2017, and has over 37 years of experience in the pharmaceutical and biotech industry. In 2015 he retired as president of BioVectra, Inc., located in Charlottetown, Prince Edward Island, Canada, and served as an executive officer with BioVectra since 1995. Following his promotion to chief operating officer in 2005, he was responsible for growth of the firm’s contract manufacturing and drug development efforts, with the firm filing numerous Drug Master Files (DMF), Investigational New Drug applications (IND), and supported the New Drug Applications for numerous clients. Mr. Zajicek successfully led BioVectra to the development of generic docetaxel, and obtained “first to file” status for this oncology drug. BioVectra partnered the product with Sandoz for the US market, and other marketing firms for markets in Canada, Europe, Middle East, North Africa, and South America. Under Mr. Zajicek’s leadership, BioVectra developed capabilities in microbial fermentation for protein-based and small molecule drugs, as well as combining biotech processing with synthetic capabilities to perform unique chemistries and conjugations of large to small molecules. Prior to joining BioVectra, Mr. Zajicek held positions in manufacturing operations, engineering, research and product development, and business development at G. D. Searle and The NutraSweet Company. Mr. Zajicek holds a BS in Chemical Engineering from Illinois Institute of Technology and a BS in Business Administration from Elmhurst College. The Company has concluded that the specific experiences, qualifications and skills described above, including, without limitation, the significant background in drug manufacturing under regulatory guidelines, constitute the skill set necessary to serve as the Company’s Director."
Wow!!! No PR coming...lol
FORM 8-K Dated November 29, 2018
Item 8.01 Other Events
The Company is halting enrollment in its Phase I clinical trial of Prolanta for the treatment of ovarian cancer as a result of injection site reactions at the current dose level. No other adverse effects or signs of toxicity have been observed for the drug.
Two subjects enrolled in the second dosing group, 1 mg per kg of body weight, have experienced inflammation and edema at the injection sites that resulted in their withdrawal from the study. Prolanta is injected subcutaneously daily during the treatment period. The Company believes that a reformulation or alternative dosing method of the drug will be required to continue the clinical evaluation of the drug, and such changes may require additional preclinical toxicity studies and additional clearance by the U.S. Food and Drug Administration. The Company does not have the financial resources at this time to conduct such additional studies.
The Company will evaluate its development plans, including accelerating its development timelines for CycloSam, its other product candidate.
.0016 at best after flippers get done...lol
That complaint is not even in the same ballpark. Redman is the master and author of the book "How to Scam Investors for Dummies".
Waste of time to file FINRA and SEC complaints. These scam artists are the best at what they do and will continue to scam investors with their false promises, dilution schemes, etc., etc., etc.
ONCX once a POS, still a POS, and always will be a POS
With all of the dilution looming, it's hard to believe why anybody would be investing in this pos. Obviously just a lot of penny stock flippers here lately.
Most recent 10Q
"In addition, as of September 30, 2018, we have outstanding options to acquire up to 6,800,000 shares of Common Stock, warrants to acquire up to 49,477,380 shares of Series A Preferred Stock (which upon exercise would be convertible into 82,462,465 shares of Common Stock) and warrants to acquire up to 251,513,750 shares of Common Stock. We may issue an additional 220,123,951 shares of Common Stock if holders of secured notes voluntarily convert. If all derivative and convertible securities were fully exercised and converted into Common Stock, there would be a total of 774,442,119 shares of Common Stock outstanding. In addition, we may be obligated to issue an additional 14,000,000 shares of Series A Preferred Stock in exchange for future clinical research services in the amount of $1,050,000."
Just a little behind
8K Dated November 29, 2018
Item 8.01 Other Events
The Company is halting enrollment in its Phase I clinical trial of Prolanta for the treatment of ovarian cancer as a result of injection site reactions at the current dose level. No other adverse effects or signs of toxicity have been observed for the drug.
Two subjects enrolled in the second dosing group, 1 mg per kg of body weight, have experienced inflammation and edema at the injection sites that resulted in their withdrawal from the study. Prolanta is injected subcutaneously daily during the treatment period. The Company believes that a reformulation or alternative dosing method of the drug will be required to continue the clinical evaluation of the drug, and such changes may require additional preclinical toxicity studies and additional clearance by the U.S. Food and Drug Administration. The Company does not have the financial resources at this time to conduct such additional studies.
The Company will evaluate its development plans, including accelerating its development timelines for CycloSam, its other product candidate.
LOL!!!!!!
Crystal ball post!!!! Took a little longer than expected, but dead on!!!!
FORM 8-K
Date of Report (Date of earliest event reported): January 23, 2019
Item 5.02 Departure of Directors or Certain Of?cers; Election of Directors; Appointment of Certain Of?cers; Compensatory Arrangements of Certain Of?cers.
On January 11, 2019, Donald Payne resigned his position as Secretary of the Company and provided written notice of his intention to terminate his part-time employment in 35 days. Mr. Payne has served as a part-time employee for several years, and committed approximately 10% of his time to the Company’s activities in late 2018. Mr. Payne also served as the principal accounting officer of the Company from April 2017 to January 2019.
New stick with new bait. Looks like fresh meat is taking the new bait lately....lol
When you look up "deception" in the future you will see a picture of Redman next to it. Injections were likely performed early 2018 and so the reactions happened quite soon after. Wonder if noteholders were aware of this BEFORE they renegotiated the notes long after that. Bet not. Wow!!!!!!
8K Dated November 29, 2018 (Released January 2, 2019)
Item 8.01 Other Events
"The Company is halting enrollment in its Phase I clinical trial of Prolanta for the treatment of ovarian cancer as a result of injection site reactions at the current dose level. No other adverse effects or signs of toxicity have been observed for the drug."
LMAO!!!!!!!
Severance packages soon!!!!
Prolanta never failed, it never got off the ground. It was real at one time, but has since faded off into the sunset. It is now a fake product to keep investors attached to the hip of this sinking ship while they seek other alternatives to keep the boat afloat. Maybe they will be somewhat successful with one or two other replacements for Prolanta, but don’t bet on it, and definitely don’t invest in it.
The only thing this turd has produced for the past year is SEC filings and acquired a license for a drug to treat Osteosarcoma (which affects ONLY 800-900 patients in the US a year). No news or updates about Prolanta, their bread and butter, and a drug which began it’s clinical trial in 2016, almost 3 years ago!!!!! The last conference they were supposed to attend was June 2018 (don’t believe they made it though) and they appear to be no longer attending or planning to attend any conferences anytime soon. Webpage hasn’t been updated in months. Net cash used in operating activities for the first nine months of the year according to the last 10Q was $1,319,639, for what??????? A membership to smallcapvoice.com that only lasted a month?????? Currently $6,664,895 in debt and 254,618,074 shares can be converted and sold starting August 1, 2019.
If it looks and sounds like a con job, it probably is. Welcome to the OTC market!
Spot on laraz!!! November just two weeks away. What will Greenville do??? Sell none??? Sell some??? Sell all??? It's about to get ugly. My thought is that the price is going up to entice them to sell and then be done with this boat anchor called Oncolix...LOL. By the way, for those who are not aware, Greenville owns 117,230,460 shares of common stock and 39,877,000 of preferred stock.
Contractual Lock-Up
Messrs. Redman and Payne have agreed until August 2019 not to sell, assign or otherwise transfer any of their shares of our Common Stock or Series A Preferred Stock. Health Sciences Center LLC has agreed until November 2018 not to sell, assign or otherwise transfer any of their shares of its Common Stock or Series A Preferred Stock.
Pablo Picasso (aka Michael Redman) is at it again....painting the close green with a couple meaningless trades of 100 just as time expires....LOL
Simple math? Usually a company has a verifiable product that provides value to somebody before it gains anything. ONCX has nothing of value except millions of dollars of worthless notes and non-existent promises.
Haha..everything NOT looking so great. November less than 30 days away and Greenville Health might unload 117,000,000+ shares.
Contractual Lock-Up
Messrs. Redman and Payne have agreed until August 2019 not to sell, assign or otherwise transfer any of their shares of our Common Stock or Series A Preferred Stock. Health Sciences Center LLC has agreed until November 2018 not to sell, assign or otherwise transfer any of their shares of its Common Stock or Series A Preferred Stock.
November should be interesting
Contractual Lock-Up
Messrs. Redman and Payne have agreed until August 2019 not to sell, assign or otherwise transfer any of their shares of our Common Stock or Series A Preferred Stock. Health Sciences Center LLC has agreed until November 2018 not to sell, assign or otherwise transfer any of their shares of its Common Stock or Series A Preferred Stock.
Note: Health Sciences Center LLC is Greenville Hospital and owns 117,230,460 shares of common stock (67.5%).
No wonder why Redman keeps his mouth shut and gives everybody the silent treatment. He is happy to keep the pps low so Greenville will not sell it's shares.
Dream on Redman!!!!!! Keep hanging those carrots on the stick and sooner or later your stick can't support all of them....LOL
"Although osteosarcoma will be our first target for this drug, the preclinical data show CycloSamTM may be superior to Xifigo, a radiopharmaceutical marketed by Bayer ($464 million sales 2017) for the treatment of bone metastases. Our drug could also be a better choice for bone marrow ablation," stated Michael Redman, CEO of Oncolix. "Furthermore, if we enter into this license agreement, we will have a strengthened pipeline of drug candidates."
Great "price action" after such a huge announcement....LOL
IGL Pharmacy no doubt working out of a rental house garage somewhere probably in a foreign country....LOL
ONCX plan for IGL is probably written on a napkin from a Hardee's restaurant....LOL
NICE "ONCX" 18% LOSS TODAY!!!UNDER .01!!!
775,000,000 million shares O/S soon???? Wow!!!! Almost 725% more than current 105,000,000. Wow!!!! What a bunch of "pooo"...lol
August 2018
Note 3 - Stockholders’ Deficit
We have 8,000,000,000 authorized shares of Common Stock, $0.0001 par value, and 250,000,000 authorized shares of preferred stock, of which 150,000,000 are designated as Series A Preferred Stock, $0.0001 par value. As of June 30, 2018, 104,477,936 shares of Common Stock were issued and outstanding, and 63,038,284 shares of Series A Preferred Stock, convertible into 105,297,802 shares of Common Stock, were issued and outstanding.
In addition, as of June 30, 2018, we have outstanding options to acquire up to 6,800,000 shares of Common Stock, warrants to acquire up to 49,477,380 shares of Series A Preferred Stock (which upon exercise would be convertible into 82,645,958 shares of Common Stock) and warrants to acquire up to 251,513,750 shares of Common Stock. We may issue an additional 224,123,951 shares of Common Stock if holders of secured notes voluntarily convert. If all derivative and convertible securities were fully exercised and converted into Common Stock, there would be a total of 774,859,397 shares of Common Stock outstanding. In addition, we may be obligated to issue an additional 14,000,000 shares of Series A Preferred Stock in exchange for future clinical research services in the amount of $1,050,000.